Tests darolutamide added to standard treatment for advanced prostate cancer
Tests darolutamide with standard care in men with advanced prostate cancer.
Key facts
- Who runs it
- Swiss Group for Clinical Cancer Research
- Where
- Barakaldo, Barcelona, Cáceres, Castello De La Plana, Córdoba, Lugo, Madrid, Oviedo, Palma, Pamplona, Sabadell, Salamanca, San Sebastián de los Reyes, Sevilla, Toledo, Valencia, and Valladolid, SpainSee the 20 sites
- Trial code
- Registry title
- SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 6 Aug 2025
- Expected to end
- 1 Jul 2030
- Type of study
- Interventional
- Record updated
- 12 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and no longer responds to hormone-lowering treatment. They have not yet had treatment for this stage. It tests adding darolutamide to standard care.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma that has spread (metastatic) and keeps growing despite castration (mCRPC); spread shown on imaging
- Earlier treatment
- Must have responded to an ARPI for at least 12 months in the hormone-sensitive stage. Must stay on GnRH analogues during the trial unless surgically castrated. Must not have had other systemic treatment for the castration-resistant stage.
Main reasons for not taking part
- A small cell component in the tumour
- Prior LuPSMA or radium 223 for prostate cancer
- Prior chemotherapy for the hormone-sensitive stage, except docetaxel
- Severe or uncontrolled heart or blood vessel disease
- Current spinal cord compression
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
- Castration resistance: tumor progression after orchiectomy or during treatment with GnRH analogues (agonists or antagonists)
- Non-surgically castrated patient agrees on ongoing use of GnRH analogues (agonists or antagonists) during the trial
- Metastatic disease, documented by imaging according to PCWG3 criteria
- Prior response to ARPI for at least 12 months in the mHSPC setting
- Adequate bone marrow, hepatic and renal functions
Who cannot take part
- Prior systemic therapy for metastatic castration-resistant disease
- Prior chemotherapy for mHSPC, except docetaxel
- Prior LuPSMA or radium 223 for prostate cancer
- Concomitant use of other anti-cancer drugs or radiotherapy except for local pain control and GnRH analogues
- Any concomitant drugs contraindicated for use with darolutamide or known hypersensitivity to darolutamide
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of darolutamide
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications
- Severe or uncontrolled cardiovascular disease
- Acute exacerbations of chronic illnesses, serious infections, or major surgery before start of treatment
- Presence of a small cell component
- Clinical or radiological evidence of current spinal cord compression
Where in Spain
- Hospital Universitario de CrucesBarakaldo, SpainTaking people
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
- Hospital del MarBarcelona, SpainTaking people
- Hospital San Pedro De AlcántaraCáceres, SpainTaking people
- Consorcio Hospitalario Provincial De CastellonCastello De La Plana, SpainTaking people
- Hospital Universitario Reina SofiaCórdoba, SpainTaking people
- Hospital Universitario Lucus AugustiLugo, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario HM SanchinarroMadrid, SpainTaking people
- Hospital Universitario Puerta de Hierro de MajadahondaMadrid, SpainTaking people
- Hospital Universitario Central De AsturiasOviedo, SpainTaking people
- University Hospital Son EspasesPalma, SpainTaking people
- Hospital Universitario de NavarraPamplona, SpainTaking people
- Parc Tauli Hospital UniversitariSabadell, SpainTaking people
- Hospital Universitario De SalamancaSalamanca, SpainTaking people
- Hospital Universitario Infanta SofiaSan Sebastián de los Reyes, SpainTaking people
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
- Hospital Universitario de ToledoToledo, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
- Hospital Clínico Universitario de ValladolidValladolid, SpainTaking people
About the trial
What the trial wants to find out
The main objective is to assess the efficacy of darolutamide, used in addition to physician-choice standard of care and then in maintenance therapy, on radiographic progression-free survival (rPFS) for patients in the first line setting of mCRPC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial
- Plain-language title
- Tests darolutamide added to standard treatment for advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 June 2026